Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS

Neurofibromatosis type 1 (NF1) is a rare neurogenetic disorder with limited treatment options. Selumetinib, a MEK1/2 inhibitor, has emerged as a promising therapy for inoperable NF1-related plexiform neurofibromas. Our retrospective pharmacovigilance study utilized the FDA Adverse Event Reporting Sy...

Celý popis

Podrobná bibliografia

Vydané v:	Frontiers in pharmacology Ročník 15; s. 1454418
Hlavný autor:	Li, Lin
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland Frontiers Media S.A 07.01.2025
Predmet:	adverse reactions FAERS neurofibromatosis type I Pharmacology rare diseases selumetinib neurofibromatosis type I rare diseases FAERS selumetinib adverse reactions
ISSN:	1663-9812, 1663-9812
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!